Clinical Trial Update: Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating PF-06651600 and PF-06700841 for efficacy and safety in alopecia areata has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alopecia Areata

Drugs mentioned

• PF-06651600 (PF-06651600)
• PF-06700841

Snippet

Sponsor: Pfizer | Conditions: Alopecia Areata | Phase 2 | Status: COMPLETED | Results posted: 2020-05-26